Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference by Lok Seng Chan, Johnson Liu, Molly S. C. Li, Lili Li, Qian Tao, Tony S. K. Mok

Get full text

Transbronchial Techniques for Lung Cancer Treatment: Where Are We Now? by Joyce W. Y. Chan, Ivan C. H. Siu, Aliss T. C. Chang, Molly S. C. Li, Rainbow W. H. Lau, Tony S. K. Mok, Calvin S. H. Ng

Get full text

Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC T... by James Chih-Hsin Yang, MD, PhD, Tony S.K. Mok, MD, Shun Lu, MD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, Yuan-Kai Shi, MD, Li Zhang, MD, Ross A. Soo, M.B.B.S., PhD, Satoshi Morita, PhD, Tomohide Tamura, MD

Get full text

A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) The... by Yvonne L. E. Ang, Xiaotian Zhao, Thanyanan Reungwetwattana, Byoung-Chul Cho, Bin-Chi Liao, Rebecca Yeung, Herbert H. Loong, Dong-Wan Kim, James Chih-Hsin Yang, Sun Min Lim, Myung-Ju Ahn, Se-Hoon Lee, Thitiporn Suwatanapongched, Kanchaporn Kongchauy, Qiuxiang Ou, Ruoying Yu, Bee Choo Tai, Boon Cher Goh, Tony S. K. Mok, Ross A. Soo

Get full text

A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score by Xinlong Zheng, Tao Lu, Shiwen Wu, Xiaoyan Lin, Jing Bai, Xiaohui Chen, Qian Miao, Jianqun Yan, Kan Jiang, Longfeng Zhang, Xiaobing Zheng, Haibo Wang, Yiquan Xu, Weijin Xiao, Cao Li, Wenying Peng, Jianming Ding, Qiaofeng Zhong, Zihua Zou, Shanshan Yang, Yujing Li, Sihui Chen, Qiuyu Zhang, Jianfeng Yan, Guofeng Tang, Yuandong Cai, Miao kang, Tony S. K. Mok, Gen Lin

Get full text

Ambient fine particulate matter inhibits 15-lipoxygenases to promote lung carcinogenesis by Ming-Yue Li, Li-Zhong Liu, Wende Li, Calvin S. H. Ng, Yi Liu, Angel W. Y. Kong, Zhili Zhao, Shanshan Wang, Haolong Qi, Hao Jia, Shucai Yang, Jing Du, Xiang Long, Rocky L. K. Ho, Ernest C. W. Chak, Innes Y. P. Wan, Tony S. K. Mok, Malcolm J. Underwood, Nirmal Kumar Gali, Zhi Ning, George G. Chen

Get full text

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042 by Aaron S. Mansfield, MD, Roy S. Herbst, MD, PhD, Gilberto de Castro, Jr., MD, PhD, Rina Hui, MB, BS, PhD, Nir Peled, MD, PhD, Dong-Wan Kim, MD, Silvia Novello, MD, PhD, Miyako Satouchi, MD, Yi-Long Wu, MD, Edward B. Garon, MD, Martin Reck, MD, PhD, Andrew G. Robinson, MD, Ayman Samkari, MD, Bilal Piperdi, MD, Victoria Ebiana, MD, Jianxin Lin, MS, Tony S.K. Mok, MD

Get full text

Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types by Jeanne Shen, Sergio Pereira, Chan-Young Ock, Yung-Jue Bang, Seulki Kim, Sehhoon Park, Se-Hoon Lee, George A Fisher, Young Kwang Chae, Yoon-La Choi, Jin-Haeng Chung, Tony S K Mok, Leeseul Kim, Jun-Eul Hwang, Gahee Park, Sanghoon Song, Seunghwan Shin, Yoojoo Lim, Wonkyung Jung, Heon Song, Hyojin Kim, Taebum Lee, Sukjun Kim, Chang Ho Ahn, Seokhwi Kim, Ben W Dulken, Stephanie Bogdan, Maggie Huang, Chiyoon Oum, Siraj M. Ali

Get full text

Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease by Molly S.C. Li, M.B.B.S., Kirsty W.C. Lee, MBChB, Kevin K.S. Mok, MBChB, Herbert H.F. Loong, M.B.B.S., K.C. Lam, MBChB, Florence S.T. Mok, M.B.B.S., Landon L. Chan, MBChB, Y.M. Lau, M.B.B.S., K.P. Chan, MBChB, Joyce T.Y. Ng, MBChB, Wesley K.Y. Wong, M.B.B.S., Benjamin H.W. Lam, M.B.B.S., Allen C.C. Chen, BM, Matthew M.P. Lee, MBChB, Olivia H. Chen, MD, PhD, Tony S.K. Mok, MD

Get full text